Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Treatment of adenoviral keratoconjuctivitis with topical Interferon alpha 2a

Poster Details

First Author: A. Tas TURKEY

Co Author(s):    U. Yolcu   S. Altun   A. Ilhan   U. Erdem           

Abstract Details


In this clinical study, we aimed to evaluate therapeutic effect of interferon α2a, and preventive effect on SEIs in adenoviral keratoconjuctivitis (AVK).


Clinical records of patients that were diagnosed as AVK retrospectively reviewed.


In all patients, if first diagnosis of AVK done by our center diluted topical recombinant interferon alfa 2a drop and preservative free artificial tears were prescribed immediately for eight times a day with for 14 days. Patients that diagnosed and referred by different center with conventional treatment regimen to our center also included the study and treatment did not changed. All patients were scheduled for visit at 2 and 4 week later


The study was consisted 345 eyes of 213 patients with AVK. Mean age of all patients was 32.616.3 (1-79) years. Interferon protocol was prescribed 262 of eyes and mean initiation time of treatment was 5.74.3 days (1 - 20). Conventional protocol was prescribed 83 eyes and mean initiation time of treatment was 3.32.4 days (1 -14). SEIs was developed 78 (29 %) eyes of interferon group and 52 (62.7%) eyes of conventional treatment group (P0.001). Mean initiation time of treatment was 4.93±3.75 days in interferon applied but no SEI developed eyes and 7.45±4.99 days in interferon applied and SEI developed eyes (P0.001).


In this study, our results indicate that interferon α2a reduces development of SEIs in respect to patient under conventional treatment and early initiation of treatment increases its effect. Topical interferon α2a was well tolerated by patients and can be an option in the treatment of AVK. Future controlled studies will qualify beneficial effect on development of SEIs in AVK.

Financial Disclosure:


Back to Poster listing